Abstract: A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.

Abstract: The present invention provides a lens driving device and an electronic device, wherein the lens driving device comprises a housing and a lens assembly; the lens assembly includes a lens module and a shell for accommodating the lens module; a bottom wall of the housing is formed an arc-shaped rail; the lens driving device further includes a ball disposed between the housing and the shell and located in the arc-shaped rail; a first driving structure for driving the lens assembly to rotate around an optical axis is further arranged between the housing and the shell; and the first driving structure includes a magnet and a coil opposite to the magnet. The present invention realizes rotation of the lens module around the optical axis direction, thus avoiding the swaying of the lens driving device caused by hand movement, achieving image stabilization, and improving the imaging effect of the lens module.

Abstract: The present invention provides a lens driving device and an electronic device, wherein the lens driving device comprises a housing and a lens assembly; the lens assembly includes a lens module and a shell for accommodating the lens module; a bottom wall of the housing is formed an arc-shaped rail; the lens driving device further includes a ball disposed between the housing and the shell and located in the arc-shaped rail; a first driving structure for driving the lens assembly to rotate around an optical axis is further arranged between the housing and the shell; and the first driving structure includes a magnet and a coil opposite to the magnet. The present invention realizes rotation of the lens module around the optical axis direction, thus avoiding the swaying of the lens driving device caused by hand movement, achieving image stabilization, and improving the imaging effect of the lens module.

Abstract: A synthetic peptide sp2 has the amino acid sequence shown in SEQ ID No: 1. sp2 has obvious anti-tumor growth activity on xenograft tumours such as subcutaneous human pancreatic cancer, human cervical cancer, and human ovarian cancer in nude mice, with a dose-effect and time-effect relation; and has the effect of delaying metastasis and prolonging the survival time of nude mouse having in situ transplantation of human pancreatic cancer and lung adenocarcinoma. After the animals were given intravenous injection of sp2 at a dose of 2000 mg/kgBW, no toxicity reaction and death were observed. The applications of sp2 also include: (1) preventing and/or treating of tumor; (2) inhibiting proliferation and/or growth and/or invasion of tumor cells; (3) enhancing the anti-tumor immune response; (4) inducing tumor cell differentiation; (5) preparing anti-tumor drugs; (6) inhibiting tumor telomerase activity; and (7) regulating the tumor cell cycle.

Abstract: A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.

Abstract: A synthetic peptide brap can be used in preparing an anti-inflammatory drug for COVID-19. The amino acid sequence of a synthetic peptide brap is as shown in SEQ ID No: 1. The synthetic bradykinin receptor antagonism peptide (brap) has significant target-docking and inhibiting effects on G-protein-coupled bradykinin B1 and B2 receptors. The intranasal administration of brap has local effects on allergic nasal inflammation, and has systemic pharmacodynamic effect on pulmonary leakage, lung injury and LPS-induced cytokine storm. The intravenous injection of brap has an obvious inhibiting effect on the excessive inflammation, oxidative stress response and serious lung injury emerging in LPS-induced mice; and has an obvious inhibiting effect on the excessive release of proinflammatory factors IL-6 and TNF-?, overexpression of IL-6 mRNA, and massive generation of reactive oxygen species (ROS) in the LPS-induced inflammatory factor storm.

Abstract: A synthetic peptide brap can be used in preparing an anti-inflammatory drug for COVID-19. The amino acid sequence of the synthetic peptide brap is as shown in SEQ ID No. 1. The synthetic peptide brap has significant target-docking and inhibiting effects on G-protein-coupled bradykinin B1 and B2 receptors; the intranasal administration of brap has local effects on allergic nasal inflammation, and has systemic pharmacodynamic effect on pulmonary leakage, lung injury and LPS-induced cytokine storm. The intravenous injection of brap has an obvious inhibiting effect on the excessive inflammation, oxidative stress response and serious lung injury emerging in LPS-induced mice; and has an obvious inhibiting effect on the excessive release of proinflammatory factors IL-6 and TNF-?, overexpression of IL-6 mRNA, and massive generation of reactive oxygen species (ROS) in the LPS-induced inflammatory factor storm.

Abstract: A synthetic peptide sp2 has the amino acid sequence shown in SEQ ID No. 1. sp2 has obvious anti-tumor growth activity on xenograft tumours such as subcutaneous human pancreatic cancer, human cervical cancer, and human ovarian cancer in nude mice, with a dose-effect and time-effect relation; and has the effect of delaying metastasis and prolonging the survival time of nude mouse having in situ transplantation of human pancreatic cancer and lung adenocarcinoma. After the animals were given intravenous injection of sp2 at a dose of 2000 mg/kgBW, no toxicity reaction and death were observed. The applications of sp2 also include: (1) preventing and/or treating of tumor; (2) inhibiting proliferation and/or growth and/or invasion of tumor cells; (3) enhancing the anti-tumor immune response; (4) inducing tumor cell differentiation; (5) preparing anti-tumor drugs; (6) inhibiting tumor telomerase activity; and (7) regulating the tumor cell cycle.

Abstract: A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.

Abstract: The patent proposes a new design of screener frame. It includes a round screener frame. There is protuberant component on the lower of screener frame to fix and connect with screener. There is protuberant sealing step on the upper of screener frame. At least one annular trough is in the middle of the screener frame ektexine and one lock-up ring for screen cloth installed in each annular trough. At the double end of lock-up ring, a special lock-up setting is connected. The new design has sealing step and annular trough in the upper and middle of screener frame ektexine. It tightens and fixes screener cloth on the frame with at least one lock-up ring. As a result, it not only has the advantage of handiness and economy, but also improves the speed to install and replace screener cloth. The most important is that the strain intensity of screener cloth has been greatly improved and accordingly the screener cloth is not easy to relax.

Abstract: An improved cytoplasmic male sterile line and improved production of hybrid soybean plants which utilizes the control of a single nuclear restorer gene to impact sterility. A cytoplasmic male sterile soybean plant is provided, wherein fertility is restored through the introduction of a dominant allele at a nuclear restorer gene locus. Maintenance of the cytoplasmic male sterile soybean line is achieved through cross pollination with a male fertile isoline wherein the isoline has a fertile cytoplasm gene and recessive alleles at a nuclear restorer gene locus. The cytoplasmic male sterile line can be used as a female in the production of hybrid soybean plants when cross-pollinated with a male sterile restorer line having dominant restorer allele at the nuclear restorer gene loci. The resulting seeds are harvested from the female plant and can be planted to grow male fertile F1 plants.